Cell Therapy Trial Launches to Heal Diabetic Foot Ulcers Faster
FibroBiologics begins a Phase 1/2 trial testing a fibroblast-spheroid cell therapy for diabetic foot ulcers in up to 120 patients.
Summary
FibroBiologics has started a Phase 1/2 clinical trial in Australia testing CYWC628, a topically applied cell therapy made from donor fibroblast spheroids, for diabetic foot ulcers. Up to 120 patients will receive either standard wound care alone or standard care plus a low or high dose of the therapy for up to 12 weeks. Diabetic foot ulcers are a serious complication of diabetes that often resist healing and can lead to amputation. Preclinical data suggest CYWC628 may significantly speed up wound closure. An interim safety and efficacy analysis is planned at six weeks. This trial represents an early but meaningful step toward a regenerative medicine solution for one of diabetes's most debilitating and life-threatening complications.
Detailed Summary
Diabetic foot ulcers are among the most serious and costly complications of diabetes, affecting millions globally and carrying a high risk of infection, amputation, and premature death. Standard wound care often fails to produce adequate healing, making new therapeutic approaches urgently needed. FibroBiologics is now testing whether a novel cell-based therapy can change that outcome.
The company has enrolled and dosed the first patients in a Phase 1/2 clinical trial evaluating CYWC628, a topically administered allogeneic fibroblast-spheroid cell therapy. The multicenter, randomized study is being conducted across multiple Australian sites following regulatory approval. Up to 120 participants will be assigned to standard care alone or standard care plus a low or high dose of CYWC628 for up to 12 weeks.
Fibroblasts are connective tissue cells central to wound repair, collagen production, and tissue regeneration. By delivering them in spheroid form — three-dimensional clusters that may better survive and function after administration — CYWC628 aims to supercharge the body's natural healing machinery. Preclinical data cited by the company suggest meaningful acceleration of wound closure compared to standard treatment.
An interim analysis is planned at six weeks to evaluate primary safety and efficacy endpoints, with ongoing monitoring using clinical and imaging assessments through the full treatment period. This phased approach allows early signals to inform dose decisions and study continuation, which is standard practice for early-phase trials.
For the broader longevity and health optimization community, this trial matters because chronic wounds are a hallmark of metabolic dysfunction and accelerated biological aging. Successful regenerative wound therapies could reduce amputation rates, hospitalizations, and diabetes-related mortality. However, this is an early-stage trial, and efficacy conclusions cannot be drawn until results are published. Readers should monitor peer-reviewed outcomes before drawing clinical conclusions.
Key Findings
- Phase 1/2 trial enrolling up to 120 diabetic foot ulcer patients across multiple Australian sites has begun.
- CYWC628 uses donor fibroblast spheroids applied topically on top of standard wound care for up to 12 weeks.
- Preclinical data suggest CYWC628 may significantly accelerate wound healing versus standard care alone.
- Interim safety and efficacy analysis planned at six weeks with full imaging and clinical monitoring throughout.
- Diabetic foot ulcers carry high amputation and mortality risk, making effective new therapies a major unmet need.
Methodology
This is a news report from Longevity.Technology summarizing a company press announcement. Evidence is based on preclinical data and trial initiation; no peer-reviewed clinical results are yet available. Source credibility is moderate — FibroBiologics is the originating party, introducing potential promotional bias.
Study Limitations
Results are not yet available; all efficacy claims are based on preclinical data provided by the sponsoring company. The trial is Phase 1/2, meaning it is primarily designed to assess safety and tolerability, not to confirm therapeutic benefit. Independent peer-reviewed publication of outcomes will be essential before clinical implications can be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.